Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience

Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience

Apremilast, a phosphodiesterase-4 inhibitor, has shown promise to have a potential beneficial metabolic effect. We conducted a single-centre retrospective study on adult patients with moderate-to-severe psoriasis who underwent apremilast treatment over at least 12 and 52 weeks, respectively. Baselin...

Full description

Bibliographic Details
Main Authors: Prisca Guerra, Antonella Di Cesare, Elia Rosi, Ilaria Scandagli, Gianmarco Silvi, Giulia Nunziati, Francesca Prignano
Format: Article
Language:English
Published: MDPI AG 2024-03-01
Series:Life
Subjects:
psoriasis
psoriatic arthritis
apremilast
comorbidities
metabolic effect
lipid profile
Online Access:https://www.mdpi.com/2075-1729/14/3/395

Similar Items

Similar Items